Clinical trials: Opiate Dependent
- Condition Opiate Dependent
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Infections, Human Immunodeficiency Virus and Hepatitis
Methadone-Dolutegravir (DTG - GSK1349572) Drug Interaction Study.
Dolutegravir (DTG, GSK1349572) is an integrase inhibitor that is currently in Phase 3 clinical development for the treatment of HIV infection.
- Trial name
- NCT01467518
- Testing
- Dolutegravir, Methadone
- Where
- Canada
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
Healthy Subjects
Co-Administration Of Fosamprenavir With Methadone: A Drug Interaction Study.
To assess the combined effects of fosamprenavir 700mg BID + ritonavir 100mg BID + standardized dose of methadone, on plasma total and unbound methadone enantiomer pharmacokinetics (PK), opiate pharmacodynamic (PD) measures, and…
- Trial name
- NCT00481182
- Testing
- fosamprenavir + ritonavir + methadone
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pain, Acute Pain
A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure to Investigate the Safety and Tolerability of GRT0151Y and to Find Out Which Single Dose of the Compound is Maximally Tolerated
The purpose of this study is to determine the maximum dose of GRT0151Y that is tolerable and to explore the safety profile of the drug. For each Treatment Period (Visits 2-5), dosing will be separated by at least one week.
- Conditions
- Pain, Acute Pain, Chronic Pain
- Trial name
- NCT03765658
- Testing
- GRT0151Y dose escalation
- Where
- Canada
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Pain, Acute Pain
A Clinical Study in Healthy Adults Who Sometimes Take Drugs for Pleasure Which Aims to Evaluate Whether GRT0151Y is Likely to be Abused
The purpose of this clinical study was to evaluate whether healthy adults, who sometimes take drugs for pleasure, are likely to abuse GRT0151Y. This abuse potential is assessed at three different doses of GRT0151Y.
- Trial name
- NCT03768024
- Testing
- GRT0151Y 50 mg capsule, Hydromorphone IR 4 mg
- Where
- Canada
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH